Compare NBIX & HTHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | HTHT |
|---|---|---|
| Founded | 1992 | 2005 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 13.6B |
| IPO Year | 1996 | 2010 |
| Metric | NBIX | HTHT |
|---|---|---|
| Price | $174.19 | $41.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 4 |
| Target Price | ★ $180.91 | $56.60 |
| AVG Volume (30 Days) | 1.1M | ★ 2.0M |
| Earning Date | 05-05-2026 | 05-19-2026 |
| Dividend Yield | N/A | ★ 4.07% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $24.73 | $7.18 |
| Revenue Next Year | $13.14 | $6.71 |
| P/E Ratio | $91.24 | ★ $30.34 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $122.14 | $30.42 |
| 52 Week High | $174.38 | $56.53 |
| Indicator | NBIX | HTHT |
|---|---|---|
| Relative Strength Index (RSI) | 67.99 | 39.70 |
| Support Level | $153.96 | $41.53 |
| Resistance Level | N/A | $45.65 |
| Average True Range (ATR) | 4.48 | 1.27 |
| MACD | 0.66 | 0.08 |
| Stochastic Oscillator | 95.56 | 28.23 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
H World Group Ltd a foremost, fast-growing multi-brand hotel group with international operations. The principal business activities of the Company are to develop and operate leased and owned, manachised and franchised hotels mainly in the PRC or PRC Mainland. The Group has two operating segments which are legacy Huazhu and legacy DH according to the way management intends to evaluate results and allocate resources within the Group. The majority of revenue comes from legacy Huazhu. The company has presence in Greater China and also Outside Greater China.